C

Compugen Ltd
D

CGEN

1.54000
USD
0.02
(1.32%)
Market Closed
Volume
7,175
EPS
-1
Div Yield
-
P/E
51
Market Cap
137,886,105
Related Instruments
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BMY
    BMY
    0.990
    (1.76%)
    57.280 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    MRNA
    MRNA
    -0.200
    (-0.51%)
    39.360 USD
    NVS
    NVS
    0.340
    (0.35%)
    97.070 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    More
News

Title: Compugen Ltd

Sector: Healthcare
Industry: Biotechnology
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.